defactinib,avutometinib
verastem
['vs-6766', 'defactinib', 'verastem']
today kicks off #asco22 in chicago. we re looking forward to presentations highlighting continued advances in ras-driven tumors, including our own research and investigator-sponsored studies of our vs-6766 raf/mek clamp and defactinib #cancerresearch 
Verastem Oncology is a biopharma company that develops medicines to improve survival and quality of life of #cancer patients. $VSTM